News
Public · Published
Moderna Stock Soars After $162 Million Profit Reverses Last Year's Loss
Moderna reported third-quarter revenue of $1.3 billion, up 29% from a year earlier, and net income of $162 million versus a loss of about $200 million last year. It raised its 2026 revenue-growth outlook to 15% to 25% and lifted its projected year-end cash balance to $8.1 billion to $8.3 billion.
Published:
Updated:
What happened
Moderna reported third-quarter revenue of $1.3 billion, up 29% from a year earlier, and net income of $162 million versus a loss of about $200 million last year. It raised its 2026 revenue-growth outlook to 15% to 25% and lifted its projected year-end cash balance to $8.1 billion to $8.3 billion.
Confirmed
Global impact / market context
The return to profit and higher sales outlook suggest stronger vaccine and collaboration revenue alongside lower expected costs. A larger projected cash balance gives Moderna more room to fund development and launches, while also reducing pressure to rely on borrowed money or raise new capital.
Analyst inference
The article attributes the improved results partly to overseas COVID-19 vaccine demand and collaboration revenue, with international markets expected to provide about half of annual sales. That makes the outlook dependent on continued demand abroad as well as progress from newer vaccines.
Analyst inference
What to watch
- Check whether overseas COVID-19 vaccine demand and collaboration revenue continue supporting sales in upcoming quarters, since they helped drive the reported revenue growth. Analyst inference
- Watch for evidence that Moderna’s reduced operating expense forecast is achieved; lower costs could help preserve the return to quarterly profitability. Analyst inference
- Track the planned limited U.S. mFLUSIVA rollout for the 2026–27 flu season and whether the melanoma vaccine developed with Merck reaches the market in 2027. Confirmed